![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » IMMUNE RESPONSE TO EXPAND HIV TREATMENT TRIAL
IMMUNE RESPONSE TO EXPAND HIV TREATMENT TRIAL
August 7, 2006
Immune Response has received approvals to expand its Phase II study of IR103 in drug-naive HIV patients to include clinical sites in France. The trial, which is currently under way at several sites in Italy, will examine IR103, a second-generation immunotherapy, as a first-line treatment for drug-naive HIV-infected individuals not yet recommended for antiretroviral therapy according to current medical guidelines.
Ultimately, more than 200 drug-naive patients will be enrolled in two parallel clinical studies being conducted in France and Italy, and Canada and the UK.
The study, which includes a rollover patient population from a previous clinical study of the company's first-generation immunotherapy, Remune, is designed to assess the safety and ability of various doses of IR103 to induce HIV-specific immunity.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct